According to real-world data, trastuzumab deruxtecan showed promising intracranial activity for patients with active brain metastases from HER2-positive or HER2-low metastatic breast cancer.
According to real-world data, trastuzumab deruxtecan showed promising intracranial activity for patients with active brain metastases from HER2-positive or HER2-low metastatic breast cancer.
A retrospective study found that patients with HR-positive, HER2-low metastatic breast cancer switched to chemotherapy after receiving 2 lines of therapy.
A retrospective study found that patients with HR-positive, HER2-low metastatic breast cancer switched to chemotherapy after receiving 2 lines of therapy.
According to results from a multinational study, use of an artificial intelligence tool during the assessment of HER2 status improved accuracy of identifying HER2-low or HER2-ultralow breast cancer.
According to results from a multinational study, use of an artificial intelligence tool during the assessment of HER2 status improved accuracy of identifying HER2-low or HER2-ultralow breast cancer.
Based on results from the phase 3 DESTINY-Breast 06 trial, the FDA has approved trastuzumab deruxtecan for patients with HR-positive, HER2-low or HER2-ultralow unresectable or metastatic breast cancer who experienced disease progression on or...
Based on results from the phase 3 DESTINY-Breast 06 trial, the FDA has approved trastuzumab deruxtecan for patients with HR-positive, HER2-low or HER2-ultralow unresectable or metastatic breast cancer who experienced disease progression on or...
According to final results from the AFT-38 PATINA trial, the addition of palbociclib to anti-HER2 therapy and endocrine therapy demonstrated a statistically significant and clinically meaningful improvement to progression-free survival among...
According to final results from the AFT-38 PATINA trial, the addition of palbociclib to anti-HER2 therapy and endocrine therapy demonstrated a statistically significant and clinically meaningful improvement to progression-free survival among...
According to results from the phase 2 MARGOT trial, margetuximab plus paclitaxel and pertuzumab did not improve the pathological complete response rate compared with trastuzumab plus paclitaxel and pertuzumab among patients with HER2-positive...
According to results from the phase 2 MARGOT trial, margetuximab plus paclitaxel and pertuzumab did not improve the pathological complete response rate compared with trastuzumab plus paclitaxel and pertuzumab among patients with HER2-positive...
Erika Hamilton, MD discusses the long-term analysis from the phase 3 DESTINY-Breast03 trial which reinforced the superiority of trastuzumab deruxtecan over trastuzumab emtansine for patients with HER2-positive metastatic breast cancer...
Erika Hamilton, MD discusses the long-term analysis from the phase 3 DESTINY-Breast03 trial which reinforced the superiority of trastuzumab deruxtecan over trastuzumab emtansine for patients with HER2-positive metastatic breast cancer...
In this video, a panel of experts discuss the management of patients with HER2-positive metastatic breast cancer, including updated results from the DESTINY-Breast03 trial.
In this video, a panel of experts discuss the management of patients with HER2-positive metastatic breast cancer, including updated results from the DESTINY-Breast03 trial.
According to updated survival results from the DESTINY-Breast03 trial, trastuzumab deruxtecan continues to show superiority over trastuzumab emtansine among patients with HER2-positive metastatic breast cancer.
According to updated survival results from the DESTINY-Breast03 trial, trastuzumab deruxtecan continues to show superiority over trastuzumab emtansine among patients with HER2-positive metastatic breast cancer.
According to first results from the phase 3 DESTINY-Breast06 trial, trastuzumab deruxtecan improved survival results among patients with HER2-low and -ultralow, HR-positive metastatic breast cancer.
According to first results from the phase 3 DESTINY-Breast06 trial, trastuzumab deruxtecan improved survival results among patients with HER2-low and -ultralow, HR-positive metastatic breast cancer.
According to real-world data, trastuzumab deruxtecan showed promising intracranial activity for patients with active brain metastases from HER2-positive or HER2-low metastatic breast cancer.
According to real-world data, trastuzumab deruxtecan showed promising intracranial activity for patients with active brain metastases from HER2-positive or HER2-low metastatic breast cancer.
A retrospective study found that patients with HR-positive, HER2-low metastatic breast cancer switched to chemotherapy after receiving 2 lines of therapy.
A retrospective study found that patients with HR-positive, HER2-low metastatic breast cancer switched to chemotherapy after receiving 2 lines of therapy.
According to results from a phase 3 trial, the addition of atezolizumab to chemotherapy plus trastuzumab and peruzumab did not increase the pathologic complete response among patients with HER2-positive breast cancer.
According to results from a phase 3 trial, the addition of atezolizumab to chemotherapy plus trastuzumab and peruzumab did not increase the pathologic complete response among patients with HER2-positive breast cancer.
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
Switching from reference trastuzumab to biosimilar trastuzumab may not have a significant effect on the frequency of infusion reaction expression or the occurrence of cardiac dysfunction among patients with HER2-positive breast cancer.
Switching from reference trastuzumab to biosimilar trastuzumab may not have a significant effect on the frequency of infusion reaction expression or the occurrence of cardiac dysfunction among patients with HER2-positive breast cancer.
In a phase 3 trial, the SB3 trastuzumab biosimilar demonstrated comparable cardiac safety to reference trastuzumab among patients with HER2-positive early or locally advanced breast cancer.
In a phase 3 trial, the SB3 trastuzumab biosimilar demonstrated comparable cardiac safety to reference trastuzumab among patients with HER2-positive early or locally advanced breast cancer.
Long-term data from a phase 2 trial found achieving pathologic complete response (pCR) after 12 weeks of chemotherapy-free, de-escalated neoadjuvant therapy was associated with excellent survival in HR-positive/HER2-positive early breast...
Long-term data from a phase 2 trial found achieving pathologic complete response (pCR) after 12 weeks of chemotherapy-free, de-escalated neoadjuvant therapy was associated with excellent survival in HR-positive/HER2-positive early breast...
The FDA granted approval to fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with HER2–positive metastatic or unresectable breast cancer previously treated with an anti-HER2-based regimen.
The FDA granted approval to fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with HER2–positive metastatic or unresectable breast cancer previously treated with an anti-HER2-based regimen.
Treatment with trastuzumab deruxtecan was associated with significantly lower risk of disease progression or death over trastuzumab emtansine in patients with HER2–positive, metastatic breast cancer.
Treatment with trastuzumab deruxtecan was associated with significantly lower risk of disease progression or death over trastuzumab emtansine in patients with HER2–positive, metastatic breast cancer.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
True or false: Trastuzumab deruxtecan was associated with significantly lower risk of disease progression over current standard of care for HER2-positive metastatic breast cancer.
True or false: Trastuzumab deruxtecan was associated with significantly lower risk of disease progression over current standard of care for HER2-positive metastatic breast cancer.
True or false: Neoadjuvant PLD plus docetaxel and trastuzumab improved pathological complete response rates in patients with invasive HER2+ breast cancer.
True or false: Neoadjuvant PLD plus docetaxel and trastuzumab improved pathological complete response rates in patients with invasive HER2+ breast cancer.
True or false: Trastuzumab plus chemotherapy demonstrated lower recurrence and mortality than chemotherapy alone in patients with early-stage HER2+ breast cancer.
True or false: Trastuzumab plus chemotherapy demonstrated lower recurrence and mortality than chemotherapy alone in patients with early-stage HER2+ breast cancer.
True or false: Interim results from a phase 2 trial found that dalpiciclib plus pyrotinib showed promise as a chemo-free regimen for patients with HER2+ breast cancer.
True or false: Interim results from a phase 2 trial found that dalpiciclib plus pyrotinib showed promise as a chemo-free regimen for patients with HER2+ breast cancer.
True or false: In a recent phase 3 study for patients with HER2-negative early breast cancer with BRCA1 or BRCA2 germline mutations, placebo induction showed superior survival benefit in comparison to adjuvant olaparib.
True or false: In a recent phase 3 study for patients with HER2-negative early breast cancer with BRCA1 or BRCA2 germline mutations, placebo induction showed superior survival benefit in comparison to adjuvant olaparib.
Results from a translational analysis of patients with high-grade glioma demonstrated that which of the following immune cell population changes distinguished long-term survivors from short-term survivors?
Results from a translational analysis of patients with high-grade glioma demonstrated that which of the following immune cell population changes distinguished long-term survivors from short-term survivors?
In patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy, which thoracic radiotherapy strategy was associated with improved survival outcomes?
In patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy, which thoracic radiotherapy strategy was associated with improved survival outcomes?
True or False: Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab does not significantly improve overall survival compared with regorafenib in patients with relapsed/refractory metastatic colorectal cancer...
True or False: Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab does not significantly improve overall survival compared with regorafenib in patients with relapsed/refractory metastatic colorectal cancer...
Did auceliciclib demonstrate acceptable tolerability and preliminary signs of clinical activity in patients with advanced solid tumors and recurrent/relapsed high-grade glioma?
Did auceliciclib demonstrate acceptable tolerability and preliminary signs of clinical activity in patients with advanced solid tumors and recurrent/relapsed high-grade glioma?
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
According to real-world data, trastuzumab deruxtecan showed promising intracranial activity for patients with active brain metastases from HER2-positive or HER2-low metastatic breast cancer.
According to real-world data, trastuzumab deruxtecan showed promising intracranial activity for patients with active brain metastases from HER2-positive or HER2-low metastatic breast cancer.
A retrospective study found that patients with HR-positive, HER2-low metastatic breast cancer switched to chemotherapy after receiving 2 lines of therapy.
A retrospective study found that patients with HR-positive, HER2-low metastatic breast cancer switched to chemotherapy after receiving 2 lines of therapy.
According to results from a phase 3 trial, the addition of atezolizumab to chemotherapy plus trastuzumab and peruzumab did not increase the pathologic complete response among patients with HER2-positive breast cancer.
According to results from a phase 3 trial, the addition of atezolizumab to chemotherapy plus trastuzumab and peruzumab did not increase the pathologic complete response among patients with HER2-positive breast cancer.
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
Switching from reference trastuzumab to biosimilar trastuzumab may not have a significant effect on the frequency of infusion reaction expression or the occurrence of cardiac dysfunction among patients with HER2-positive breast cancer.
Switching from reference trastuzumab to biosimilar trastuzumab may not have a significant effect on the frequency of infusion reaction expression or the occurrence of cardiac dysfunction among patients with HER2-positive breast cancer.
In a phase 3 trial, the SB3 trastuzumab biosimilar demonstrated comparable cardiac safety to reference trastuzumab among patients with HER2-positive early or locally advanced breast cancer.
In a phase 3 trial, the SB3 trastuzumab biosimilar demonstrated comparable cardiac safety to reference trastuzumab among patients with HER2-positive early or locally advanced breast cancer.
Long-term data from a phase 2 trial found achieving pathologic complete response (pCR) after 12 weeks of chemotherapy-free, de-escalated neoadjuvant therapy was associated with excellent survival in HR-positive/HER2-positive early breast...
Long-term data from a phase 2 trial found achieving pathologic complete response (pCR) after 12 weeks of chemotherapy-free, de-escalated neoadjuvant therapy was associated with excellent survival in HR-positive/HER2-positive early breast...
The FDA granted approval to fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with HER2–positive metastatic or unresectable breast cancer previously treated with an anti-HER2-based regimen.
The FDA granted approval to fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with HER2–positive metastatic or unresectable breast cancer previously treated with an anti-HER2-based regimen.
Treatment with trastuzumab deruxtecan was associated with significantly lower risk of disease progression or death over trastuzumab emtansine in patients with HER2–positive, metastatic breast cancer.
Treatment with trastuzumab deruxtecan was associated with significantly lower risk of disease progression or death over trastuzumab emtansine in patients with HER2–positive, metastatic breast cancer.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
